Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure

Febrile neutropenia (FN) is a serious complication of chemotherapy, which can cause significant morbidity and mortality, result in dose delays and reductions and, ultimately, reduce cancer survival. Over the past decade, the availability of biosimilar filgrastim (short-acting granulocyte colony-stimulating factor [G-CSF]) has transformed patient access, with clear evidence of clinical benefit at preventing FN at reduced costs. In 2019, seven biosimilar pegfilgrastims (long-acting G-CSFs) were licensed, creating optimal market conditions and choice for prescribers. FN affects up to 117 per 1000 cancer patients, with mortality rates in the range of 2–21%. By reducing FN incidence and improving chemotherapy relative dose intensity (RDI), G-CSF has been associated with a 3.2% absolute survival benefit. Guidelines recommend primary prophylaxis and that filgrastim be administered for 10–14 days, while pegfilgrastim is administered once per cycle. When taken according to the guidelines, pegfilgrastim and filgrastim are equally effective. However, in routine clinical practice, filgrastim is often under-dosed (< 7 days) and has been shown to be inferior to pegfilgrastim at reducing FN incidence, hospitalisations and maintaining RDI. Once-per-cycle administration with pegfilgrastim might also aid patient adherence. The introduction of biosimilar pegfilgrastim should instigate a rethink of neutropenia management. Biosimilar pegfilgrastim

Measurement of the B+ production cross section in pp collisions at √s = 7 TeV

This is the pre-print version of the Published Article which can be accessed from the link below.Measurements of the total and differential cross sections dσ/dpTB and dσ/dyB for B+ mesons produced in pp collisions at √s=7  TeV are presented. The data correspond to an integrated luminosity of 5.8  pb-1 collected by the CMS experiment operating at the LHC. The exclusive decay B+→J/ψK+, with J/ψ→μ+μ-, is used to detect B+ mesons and to measure the production cross section as a function of pTB and yB. The total cross section for pTB>5  GeV and |yB|<2.4 is measured to be 28.1±2.4±2.0±3.1  μb, where the first uncertainty is statistical, the second is systematic, and the last is from the luminosity measurement

Measurement of the B+ Production Cross Section in pp Collisions at root s=7 TeV

Measurements of the total and differential cross sections d sigma/dp(T)(B) and d sigma/dy(B) for B+ mesons produced in pp collisions at root s = 7 TeV are presented. The data correspond to an integrated luminosity of 5.8 pb(-1) collected by the CMS experiment operating at the LHC. The exclusive decay B+ -> J/psi K+, with J/psi -> mu(+)mu(-), is used to detect B+ mesons and to measure the production cross section as a function of p(T)(B) and y(B). The total cross section for p(T)(B) > 5 GeV and vertical bar y(B)vertical bar < 2.4 is measured to be 28.1 +/- 2.4 +/- 2.0 +/- 3.1 mu b, where the first uncertainty is statistical, the second is systematic, and the last is from the luminosity measurement